Attralus Debuts at #1 in Company Rating
Attralus entered the Eternal Search company rating at #1 of 196 with score 46.04, showing high scientific testability (falsifiability 9) but a wide gap between claims and public evidence (claim integrity 2).
Attralus was not on the Eternal Search company rating last week. This week: #1 of 196 companies, score 46.04. GlycanAge, the previous leader, dropped out entirely.
Systemic amyloidosis: misfolded proteins (amyloid) accumulate in organs and destroy them. Attralus is developing therapeutics for complete amyloid removal across all types and stages of the disease. Their technology led to the world's first amyloidosis-specific imaging agent, which Bayer acquired.
Falsifiability is the top score at 9: the hypotheses are testable. Premise plausibility 8, implementation fidelity 8. But claim integrity is only 2, meaning more is claimed than demonstrated. Media reach 4, independent replication 4.
Testable science, solid premise, thin public evidence so far.
https://eternalsearch.net/companies/0mX7XqHD
Attralus went from unranked to #1 in one week, the most dramatic single-entity entrance in the company rating this period.